NCT04610528View on ClinicalTrials.gov

A Window-of-opportunity Study of U3-1402, a HER3-targeting Antibody-drug Conjugate in Operable Breast Cancer According to ERBB3 Expression

EARLY_PHASE1UnknownINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

December 22, 2020

Primary Completion Date

January 30, 2022

Study Completion Date

September 30, 2023

Conditions
Breast Cancer
Interventions
DRUG

U3 1402

6.4 mg/kg dose

DRUG

U3 1402

5.6 mg/kg dose

Trial Locations (10)

38320

Hospital Universitario de Canarias, Santa Cruz de Tenerife

Unknown

ICO Badalona, Badalona

Institut Català d'Oncologia Hospitalet, L'Hospitalet de Llobregat

Hospital Universitario de Fuenlabrada, Fuenlabrada

Centro Integral Oncológico Clara Campal (CIOCC), Madrid

Hospital Universitario 12 de Octubre, Madrid

Hospital Universitario Virgen del Rocio, Seville

Hospital Clinico Universitario de Valencia, Valencia

08035

Hospital Universitari Vall d'Hebrón, Barcelona

08036

Hospital Clínic de Barcelona, Barcelona

Sponsors

Collaborators (1)

Daiichi Sankyo
All Listed Sponsors
collaborator

Daiichi Sankyo

INDUSTRY

lead

SOLTI Breast Cancer Research Group

OTHER

NCT04610528 - A Window-of-opportunity Study of U3-1402, a HER3-targeting Antibody-drug Conjugate in Operable Breast Cancer According to ERBB3 Expression | Biotech Hunter | Biotech Hunter